Triple combination therapy to improve blood pressure control: experience with olmesartan–amlodipine–hydrochlorothiazide therapy

Bibliography

• Tocci G, Sciarretta S, Facciolo C, Volpe M. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension. Expert Rev Cardiovasc Ther 2007;5(4):767-76
   PubMedGoogle Scholar
• Turnbull F, Neal B, Algert C, Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005;165(12):1410-19
   PubMedGoogle Scholar
• Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362(9395):1527-35
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Ninomiya T, Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008;336(7653):1121-3
   PubMed Web of Science ®Google Scholar
• Williams B. The year in hypertension. J Am Coll Cardiol 2009;55(1):65-73
   PubMed Web of Science ®Google Scholar
• Kotseva K, Wood D, De Backer G, Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 373(9667):929-40.2009
   PubMed Web of Science ®Google Scholar
• Whyte JL, Lapuerta P, L'Italien GJ, Franklin SS. The challenge of controlling systolic blood pressure: data from the National Health and Nutrition Examination Survey (NHANES III), 1988-1994. J Clin Hypertens (Greenwich) 2001;3(4):211-16
   PubMedGoogle Scholar
• Wolf-Maier K, Cooper RS, Kramer H, Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43(1):10-17
   PubMed Web of Science ®Google Scholar
• Bramlage P, Bohm M, Volpe M, A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. J Clin Hypertens (Greenwich) 2010;12(9):666-77
   PubMed Web of Science ®Google Scholar
• Volpe M, Tocci G. Challenging hypertension: how to diagnose and treat resistant hypertension in daily clinical practice. Expert Rev Cardiovasc Ther 2010;8(6):811-20
   PubMedGoogle Scholar
• Tocci G, Giovannelli F, Sciarretta S, Management of hypertension and stroke prevention: results of the Italian cardiologist survey. Int J Clin Pract 2009;63(2):207-16
   PubMed Web of Science ®Google Scholar
• Chrysant SG. Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan/HCT). Expert Rev Cardiovasc Ther 2003;1(3):335-43
   PubMedGoogle Scholar
• Tocci G, Palano F, Pagannone E, Fixed-combination therapies in hypertension management: focus on enalapril/lercanidipine. Expert Rev Cardiovasc Ther 2009;7(2):115-23
   PubMedGoogle Scholar
• Mancia G, De Backer G, Dominiczak A, 2007 ESH-ESC Practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 2007;25(9):1751-62
   PubMed Web of Science ®Google Scholar
• Chobanian AV; Shattuck Lecture. The hypertension paradox–more uncontrolled disease despite improved therapy. N Engl J Med 2009;361(9):878-87
   PubMed Web of Science ®Google Scholar
• Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55(2):399-407
   PubMed Web of Science ®Google Scholar
• Corrao G, Parodi A, Zambon A, Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens 2010;28(7):1584-90
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42(6):1206-52
   PubMed Web of Science ®Google Scholar
• Williams B, Poulter NR, Brown MJ, British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328(7440):634-40
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27(11):2121-58
   PubMed Web of Science ®Google Scholar
• Angeli F, Verdecchia P, Reboldi GP, Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens 2004;17(9):817-22
   PubMed Web of Science ®Google Scholar
• Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003;21(6):1055-76
   PubMed Web of Science ®Google Scholar
• Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002;20(8):1461-4
   PubMed Web of Science ®Google Scholar
• Leonetti G, Cuspidi C, Facchini M. [Antihypertensive therapy in the elderly: results of large trials]. Ital Heart J Suppl 2001;2(11):1161-9
   PubMedGoogle Scholar
• Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981-97
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR, Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366(9489):895-906
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL, Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. N Engl J Med 2008;359(23):2417-28
   PubMed Web of Science ®Google Scholar
• Volpe M, Tocci G, Pagannone E. Fewer mega-trials and more clinically oriented studies in hypertension research? The case of blocking the renin-angiotensin-aldosterone system. J Am Soc Nephrol 2006;17(4 Suppl 2):S36-43
   Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359(9311):995-1003
   PubMed Web of Science ®Google Scholar
• Messerli FH, Michalewicz L. Cardiac effects of combination therapy. Am J Hypertens 1997;10(7 Pt 2):146S-52S
   Web of Science ®Google Scholar
• Messerli FH, Grossman E, Michalewicz L. Combination therapy and target organ protection in hypertension and diabetes mellitus. Am J Hypertens 1997;10(9 Pt 2):198S-201S
   Web of Science ®Google Scholar
• Messerli FH. Combination therapy in hypertension. J Hum Hypertens 1992;6(Suppl 2):S19-21
   PubMed Web of Science ®Google Scholar
• Bangalore S, Shahane A, Parkar S, Messerli FH. Compliance and fixed-dose combination therapy. Curr Hypertens Rep 2007;9(3):184-9
   PubMed Web of Science ®Google Scholar
• Ruschitzka FT, Noll G, Luscher TF. Combination of ACE inhibitors and calcium antagonists: a logical approach. J Cardiovasc Pharmacol 1998;31(Suppl 2):S5-16
   PubMedGoogle Scholar
• Corrao G, Zambon A, Parodi A, Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008;26(4):819-24
   PubMed Web of Science ®Google Scholar
• Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002;62(9):1345-53. discussion 1354-1346
   PubMed Web of Science ®Google Scholar
• Volpe M, Musumeci B, De Paolis P, Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease? J Hypertens 2003;21(8):1429-43
   PubMed Web of Science ®Google Scholar
• Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 2008;68(9):1239-72
   PubMed Web of Science ®Google Scholar
• Unger T, McInnes GT, Neutel JM, Bohm M. The role of olmesartan medoxomil in the management of hypertension. Drugs 2004;64(24):2731-9
   PubMed Web of Science ®Google Scholar
• Fabia MJ, Abdilla N, Oltra R, Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007;25(7):1327-36
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Chrysant GS. Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Opin Pharmacother 2004;5(3):657-67
   PubMed Web of Science ®Google Scholar
• Chrysant SG. Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension. Expert Rev Cardiovasc Ther 2009;7(8):887-95
   PubMedGoogle Scholar
• Punzi HA. Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Rev Cardiovasc Ther 2009;7(3):229-39
   PubMedGoogle Scholar
• Barrios V, Boccanelli A, Ewald S, Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST study. Clin Drug Investig 2007;27(8):545-58
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Melino M, Karki S, The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008;30(4):587-604
   PubMed Web of Science ®Google Scholar
• Volpe M, Brommer P, Haag U, Miele C. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig 2009;29(1):11-25
   PubMed Web of Science ®Google Scholar
• Deeks ED. Olmesartan medoxomil/amlodipine/hydrochlorothiazide: fixed-dose combination in hypertension. Drugs 2011;71(2):209-20
   PubMed Web of Science ®Google Scholar
• Neutel JM, Smith DH, Weber MA, Use of an olmesartan medoxomil-based treatment algorithm for hypertension control. J Clin Hypertens (Greenwich) 2004;6(4):168-74
   PubMedGoogle Scholar
• Volpe M, Miele C, Haag U. Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin Drug Investig 2009;29(6):381-91
   PubMed Web of Science ®Google Scholar
• Weir MR, Hsueh WA, Nesbitt SD, A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil +/- hydrochlorothiazide. J Clin Hypertens (Greenwich) 2011;13(6):404-12
   PubMed Web of Science ®Google Scholar
• Oparil S, Melino M, Lee J, Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther 2010;32(7):1252-69
   PubMed Web of Science ®Google Scholar
• Volpe M, Christian Rump L, Ammentorp B, Laeis P. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig 2012;32(10):649-64
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Izzo JL Jr, Kereiakes DJ, Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study. J Am Soc Hypertens 2012;6(2):132-41
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Littlejohn T III, Izzo JL Jr, Triple-Combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study. Am J Cardiovasc Drugs 2012;12(4):233-43
   PubMed Web of Science ®Google Scholar